Published on November 21, 2012 at 11:55 PM
Cynosure, Inc. (NASDAQ: CYNO) (the "Company"), a leader in laser- and light-based treatments for minimally invasive and non-invasive aesthetic applications, today announced the closing of its previously announced underwritten registered public offering of class A common stock. The Company also announced that Leerink Swann LLC, the sole underwriter for the offering, exercised in full its option to purchase an additional 240,000 shares of class A common stock from the Company and an additional 240,000 shares of class A common stock from El.En. S.p.A., as selling stockholder, at the public offering price, less underwriting discounts and commissions. As a result of this option exercise, the total number of shares of class A common stock sold in the offering was 3,680,000 shares. The Company received aggregate net proceeds, after deducting underwriting discounts and commissions and other estimated offering expenses, of approximately $55.35 million.
The Company intends to use the net proceeds from the shares sold in the offering for general corporate purposes and to fund its potential acquisition of complementary products, technologies or businesses. The Company did not receive any proceeds from the sale of the shares by El.En. S.p.A.
The shares described above were offered by the Company and the selling stockholder pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission (the "SEC") and declared effective on October 26, 2012. The final prospectus supplement and accompanying prospectus related to the offering have been filed with the SEC. Copies of the final prospectus supplement and accompanying base prospectus may also be obtained from Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by calling (800) 808-7525, ext. 4814.
SOURCE Cynosure, Inc.